Okay, let's tackle this question about the physiology of surfactant. The user wants a detailed explanation for an MCQ, so I need to follow the structure they provided.

First, the core concept. Surfactant is a key topic in respiratory physiology. I should mention its main components and function. Surfactant is produced by type II alveolar cells and reduces surface tension. That's the core.

Next, the correct answer. The user didn't specify the options, but common true statements about surfactant include its role in preventing alveolar collapse, being composed of phospholipids like DPPC, and being deficient in RDS of newborns. Let's assume the correct answer is about reducing surface tension and preventing atelectasis.

Then, the wrong options. Common distractors might be incorrect functions like increasing compliance (but surfactant actually increases compliance by reducing surface tension), being produced by type I cells (which is wrong because type II cells produce it), or thinking it's a glycoprotein (it's mostly phospholipids). Each of these needs a concise explanation of why they're incorrect.

Clinical pearl: Surfactant deficiency in preterm infants leads to RDS. Treatment with exogenous surfactant is a key intervention. That's a high-yield fact for exams.

Make sure each section is concise, uses bold for key terms, and stays within the character limit. Check that all parts are covered: Core Concept, Why Correct, Why Wrong, Clinical Pearl, and Correct Answer line. Avoid markdown except for bold and line breaks. Use precise terminology like DPPC, alveolar type II cells, etc.

**Core Concept**
Pulmonary surfactant is a lipoprotein complex produced by alveolar type II pneumocytes that reduces alveolar surface tension. Its primary component is **dipalmitoylphosphatidylcholine (DPPC)**, which prevents alveolar collapse during exhalation by countering the **Law of Laplace** (surface tension = 2T/r).

**Why the Correct Answer is Right**
Surfactant **lowers surface tension** in alveoli, maintaining alveolar stability and preventing atelectasis. It also **increases lung compliance** by reducing the work of breathing. The **phospholipid** component (DPPC) forms a monolayer at the air-liquid interface, disrupting cohesive forces of water molecules. This is critical in neonates; surfactant deficiency causes respiratory distress syndrome (RDS).

**Why Each Wrong Option is Incorrect**
**Option A:** “Surfactant increases surface tension” is incorrect because surfactant *reduces* surface tension.
**Option B:** “Produced by alveolar type I cells” is wrong; type II cells synthesize and secrete surfactant.
**Option C:** “Composed mainly of glycoproteins” is false; surfactant is ~90% phospholipids, with 10% proteins (SP-A, SP-B, SP-C).

**Clinical Pearl / High-Yield Fact**
Premature infants (<28 weeks) often lack sufficient surfactant, leading to RDS. Exogenous surfactant therapy (e.g., Curosurf) is administered via endotracheal tube and

✓ Correct Answer: C. SP-A plays a major role in innate host defense of the lung